National Coverage Analysis (NCA) for Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (CAG-00422N)
Select the ’Print Record’, ‘Add to Basket’ or ‘Email Record’ buttons to print the record, to add it to your basket or to email the record.
Leslye Fitterman, PhD
410-786-1806
Original Consideration for Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (this document)